Human cytomegalovirus co-opts FcRn-mediated IgG transport across trophoblast barriers

Every pregnancy is a delicate negotiation between two separate immune systems. The mother's body must protect her own health while simultaneously shielding the developing fetus from the outside world. To do this, the placenta builds a formidable wall of cells called the syncytiotrophoblast. This barrier is designed to be selective: it blocks most pathogens, such as bacteria and viruses, from crossing over, yet it has a special, essential duty to let the mother's protective antibodies pass through. These antibodies, known as IgG, are the body's memory of past infections, and the placenta uses a specific molecular shuttle, the neonatal Fc receptor, to ferry them across to the baby. This transfer provides the newborn with a temporary shield against disease during their first few months of life. However, this very mechanism of protection contains a hidden vulnerability. Because the placenta is programmed to actively transport these antibodies, a clever pathogen could potentially hijack the shuttle, using the mother's own immune defenses as a vehicle to breach the barrier and infect the child.

This is precisely the scenario researchers at the University Medical Center Freiburg and Duke University have uncovered regarding human cytomegalovirus, or HCMV. While it has long been known that this virus can cause severe birth defects, including hearing loss and developmental delays, a puzzling mystery remained: how does the virus cross the placenta when the mother already has antibodies against it? In many cases, a mother's immune system produces neutralizing antibodies that should stop the virus, yet the infection still occurs. The new study reveals that the virus does not fight its way through the barrier; instead, it disguises itself as a passenger. The virus carries special proteins on its surface that grab onto the mother's antibodies. Once attached, the virus effectively tricks the placenta's transport system into carrying the infectious particle across the barrier, right alongside the protective antibodies it was meant to deliver.

The researchers demonstrated this process using human placental cells grown in the lab to mimic the natural barrier. They found that when they added human antibodies to the virus, the amount of virus crossing the cell layer increased significantly. Without the antibodies, the virus struggled to pass through. Crucially, the study identified the specific molecular keys the virus uses to open this door. The virus relies on two of its own surface proteins, named gp34 and gp68, to bind to the antibodies. These proteins act as a bridge, connecting the virus to the placenta's transport receptor. When the researchers genetically removed these viral proteins, the virus lost its ability to cross the barrier, even in the presence of antibodies. Similarly, when they blocked the placenta's transport receptor, the virus was stopped dead in its tracks. This confirmed that the virus is not merely drifting across; it is actively co-opting the mother's immune transport system.

A particularly striking discovery was that the virus can cross the barrier even when the antibodies attached to it are capable of neutralizing it. In the lab, the team tested blood serum from pregnant women who had recently been infected with the virus. They separated these women into two groups: those whose babies became infected and those whose babies remained healthy. The serum from both groups contained antibodies that could neutralize the virus in a test tube. However, when the researchers tested how much infectious virus crossed the placental barrier using these different sera, they found a difference. The serum from mothers whose babies got infected allowed more infectious virus to pass through than the serum from mothers whose babies stayed healthy. This suggests that while the antibodies can disable the virus in some contexts, the act of crossing the placenta is a separate process. The virus can hitch a ride on the antibody shuttle even if that antibody is trying to stop it, provided the virus has the right proteins to hold on.

The study also looked at the specific roles of the two viral proteins involved. The protein gp34 appears to help the virus grab onto the transport receptor, acting as an anchor. The protein gp68, on the other hand, seems to help the virus let go once it has reached the other side of the barrier. The researchers propose a coordinated mechanism where the virus first attaches to the mother's side of the placenta using gp34, travels through the cell, and then uses gp68 to detach on the fetal side. This two-step process ensures the virus moves in the correct direction. The findings were not limited to human cells; the researchers showed that a related virus found in rhesus monkeys uses a similar strategy, suggesting this is an ancient and conserved trick used by cytomegaloviruses to survive and spread.

These results offer a new explanation for why treatments using hyperimmune globulin, which are essentially concentrated doses of antibodies, have shown mixed results in preventing congenital infection. If the virus can use the antibodies as a transport vehicle, simply adding more antibodies might not be enough to stop the infection. In some cases, the antibodies might even facilitate the virus's journey across the placenta rather than blocking it. The study concludes that the virus has evolved to exploit a fundamental biological process designed for the baby's safety. By identifying the specific viral proteins that enable this hijacking, the research points to new potential targets for intervention. Instead of just trying to boost the mother's antibody levels, future treatments might focus on blocking the viral proteins that allow the virus to grab onto the transport system, thereby preventing it from using the mother's own defenses to cross the placental barrier.